Search results for "Pharmacokinetic"

showing 10 items of 474 documents

Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime.

2004

Since oligopeptidic drugs such as beta-lactam antibiotics share the same carriers in humans and animals, the absorption and elimination kinetics of cefuroxime (C) were investigated in rats. Plasma C concentrations were measured by liquid chromatography. Pharmacokinetics and bioavailability of C in the rat were examined after intravenous (i.v.) administration at three doses (1.78, 8.9 and 17.8mg) of cefuroxime sodium and oral administration at two doses (2.02 and 8.9mg) of cefuroxime axetil (CA). Preliminary fits using data from intravenous administration of C showed that the drug disposition kinetics were clearly nonlinear, with an increase in plasma clearance as the intravenous dose increa…

MaleTime FactorsPopulationPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalIntestinal absorptionPharmacokineticsOral administrationmedicineAnimalsRats WistareducationAntibacterial agenteducation.field_of_studyCefuroximeChemistryBioavailabilityAnti-Bacterial AgentsRatsNonlinear DynamicsInjections IntravenousCefuroxime SodiumCefuroximemedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Transdermal iontophoresis of dexamethasone sodium phosphate in vitro and in vivo: effect of experimental parameters and skin type on drug stability a…

2010

The aim of this study was to investigate the cathodal iontophoresis of dexamethasone sodium phosphate (DEX-P) in vitro and in vivo and to determine the feasibility of delivering therapeutic amounts of the drug for the treatment of chemotherapy-induced emesis. Stability studies, performed to investigate the susceptibility of the phosphate ester linkage to hydrolysis, confirmed that conversion of DEX-P to dexamethasone (DEX) upon exposure to samples of human, porcine and rat dermis for 7 h was limited (82.2+/-0.4%, 72.5+/-4.8% and 78.6+/-6.0% remained intact) and did not point to any major inter-species differences. Iontophoretic transport of DEX-P across dermatomed porcine skin (0.75 mm thic…

MaleTime FactorsVomitingSwineSkin AbsorptionPharmaceutical ScienceAntineoplastic AgentsPharmacologyAdministration CutaneousHigh-performance liquid chromatographyDexamethasoneGlucocorticoids/administration & dosage/pharmacokineticsDexamethasone Sodium PhosphatePharmacokineticsDrug StabilitySpecies SpecificityIn vivoAnimalsHumansSkin/metabolismVomiting/chemically induced/prevention & controlRats WistarGlucocorticoidsTransdermalSkinddc:615IontophoresisDose-Response Relationship DrugChemistryHydrolysisGeneral MedicineAntineoplastic Agents/adverse effectsPermeationIontophoresisRatsDose–response relationshipDexamethasone/administration & dosage/analogs & derivatives/pharmacokineticsBiotechnologyNuclear chemistry
researchProduct

Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats

1977

Abstract The elimination, distribution and anticoagulant activity of S(—)-, R(+)-, and R,S(±)-phenprocoumon were determined in male Wistar-Lewis rats after intravenous injection of a single dose of 0·6 mg kg−1. From the plasma concentrations which elicited the same anticoagulant effect, S(—)-phenprocoumon was 4 to 5 times more potent than R(+)-phenprocoumon. The potency of the racemate was between those of the enantiomers. The mean biologic half-life of the S(—)-enantiomer was shorter (12·5 h) than that of R(+)-phenprocoumon (17·8 h). No differences were observed in the apparent volume of distribution. However, the mean liver: plasma concentration ratio was higher for the S(—)-(6·9) than fo…

MaleTime Factorsmedicine.drug_classPharmaceutical ScienceIn Vitro TechniquesPharmacologyPhenprocoumonPharmacokineticsmedicineAnimalsPotencyDistribution (pharmacology)PharmacologyVolume of distributionChemistryAnticoagulantAnticoagulantsRats Inbred StrainsStereoisomerism4-HydroxycoumarinsBlood ProteinsRatsKineticsLiverPhenprocoumonStereoselectivityBlood Coagulation TestsEnantiomerProtein Bindingmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Local Delivery of Nimodipine by Prolonged-Release Microparticles—Feasibility, Effectiveness and Dose-Finding in Experimental Subarachnoid Hemorrhage

2012

Background and purposeTo investigate the effect of locally applied nimodipine prolonged-release microparticles on angiographic vasospasm and secondary brain injury after experimental subarachnoid hemorrhage (SAH).Methods70 male Wistar rats were categorized into three groups: 1) sham operated animals (control), 2) animals with SAH only (control) and the 3) treatment group. SAH was induced using the double hemorrhage model. The treatment group received different concentrations (20%, 30% or 40%) of nimodipine microparticles. Angiographic vasospasm was assessed 5 days later using digital subtraction angiography (DSA). Histological analysis of frozen sections was performed using H&E-staining as …

MaleVasodilator AgentsGene ExpressionPolylactic Acid-Polyglycolic Acid CopolymerVasospasm IntracranialDrug DistributionMultidisciplinarymedicine.diagnostic_testMicrofilament ProteinsQRBrainIntracranial ArteryVasospasmAnimal ModelsImmunohistochemistryHemorrhagic StrokeNeurologyAnesthesiaInjections IntravenousToxicityMedicinemedicine.symptomMicrotubule-Associated ProteinsResearch Articlemedicine.drugDrugs and DevicesDrug Research and DevelopmentSubarachnoid hemorrhageCerebrovascular DiseasesScienceNeurosurgeryBrain damageDrug Administration ScheduleModel OrganismsmedicineAnimalsPharmacokineticsLactic Acidcardiovascular diseasesRats WistarBiologyNimodipineDose-Response Relationship Drugbusiness.industryCalcium-Binding ProteinsAngiography Digital SubtractionDigital subtraction angiographySubarachnoid Hemorrhagemedicine.diseaseRatsnervous system diseasesDelayed-Action PreparationsAngiographyRatNimodipineSurgerybusinessPolyglycolic AcidPLoS ONE
researchProduct

Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation

2018

Sirolimus appears to protect against cytomegalovirus (CMV) in organ transplant recipients. The effect of this drug in allogeneic hematopoietic stem cell transplantation recipients remains unexplored. By means of multivariate continuous-time Markov model analyses, we identified 3 independent covariates that significantly impacted the risk of CMV DNAemia: recipient/donor CMV serostatus, tacrolimus exposure, and sirolimus exposure. CMV-seropositive recipients with CMV-seronegative donors had a significantly higher probability of having detectable CMV DNAemia. Increasing the tacrolimus trough concentration from 0 to 16 ng/mL increased the probability of patients having detectable CMV DNAemia by…

Malebasic (laboratory) research/science0301 basic medicinemedicine.medical_treatmentCytomegalovirusHematopoietic stem cell transplantationGastroenterologyOrgan transplantation0302 clinical medicineRisk FactorsImmunology and AllergyPharmacology (medical)Whole bloodIncidenceHematopoietic Stem Cell Transplantationvirus diseasesMiddle AgedPrognosissurgical procedures operativeCytomegalovirus Infectionscytomegalovirus (CMV) [infection and infectious agents-viral]Femaleantiviral [antibiotic]pharmacokinetics/pharmacodynamicsImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtyinfectious diseasesirolimus [immunosuppressant-mechanistic target of rapamycin]clinical research/practicetacrolimus [immunosuppressant-calcineurin inhibitor]03 medical and health sciencesInternal medicinemedicineHumansTransplantation HomologousTrough ConcentrationViremiabone marrow/hematopoietic stem cell transplantationAgedSirolimusTransplantationbusiness.industryTransplant RecipientsTacrolimus030104 developmental biologySpainRelative riskSirolimusDNA ViralpharmacologybusinessSerostatusFollow-Up Studies030215 immunology
researchProduct

Labetalol absorption kinetics: Rat small intestine and colon studies

2006

Labetalol is a widely used drug for the management of hypertension, which is preferably administered by the oral route despite its low bioavailability. The objective of this study is to ascertain the mechanisms underlying its absorption as an approach to help in predicting the influence of dosage changes, possible drug-drug and drug-fruit juice interactions. Perfusion experiments have been performed in rats in two sites of absorption: the intestine and the colon. The nonlinearity of the process has been established by means of the assay of a wide range of concentrations (2-2000 microM). Fitting of the concentration versus time data allows the estimation of passive diffusion constant in the …

MalebiologyColonChemistryPharmaceutical ScienceAbsorption (skin)PharmacologyIntestinal absorptionSmall intestineRatsBioavailabilitymedicine.anatomical_structureIntestinal AbsorptionPharmacokineticsIntestine Smallmedicinebiology.proteinAnimalsLabetalolEffluxRats WistarLabetalolmedicine.drugP-glycoproteinJournal of Pharmaceutical Sciences
researchProduct

Modelling intestinal absorption of salbutamol sulphate in rats

2005

The objective was to develop a semiphysiological population pharmacokinetic model that describes the complex salbutamol sulphate absorption in rat small intestine. In situ techniques were used to characterize the salbutamol sulphate absorption at different concentrations (range: 0.15-18 mM). Salbutamol sulphate at concentration of 0.29 mM was administered in presence of verapamil (10 and 20 mM), grapefruit juice and sodium azide (NaN3) (0.3, 3 and 6 mM). Different pharmacokinetic models were fitted to the dataset using NONMEM. Parametric and non-parametric bootstrap analyses were employed as internal model evaluation techniques. The validated model suggested instantaneous equilibrium betwee…

Malefood.ingredientEnterocytePopulationBiological AvailabilityBiological Transport ActivePharmaceutical ScienceLumen (anatomy)PharmacologyModels BiologicalGrapefruit juiceIntestinal absorptionBeveragesfoodPharmacokineticsIntestine SmallmedicineAnimalsCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsAlbuterolATP Binding Cassette Transporter Subfamily B Member 1Rats WistarSodium Azideeducationeducation.field_of_studyChromatographyDose-Response Relationship DrugChemistryAdrenergic beta-AgonistsRatsBioavailabilitymedicine.anatomical_structureIntestinal AbsorptionVerapamilSalbutamolCitrus paradisimedicine.drugInternational Journal of Pharmaceutics
researchProduct

Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats

2015

Palmitoylethanolamide (PEA) has antinflammatory and antinociceptive properties widely exploited in veterinary and human medicine, despite its poor pharmacokinetics. Looking for prodrugs that could progressively release PEA to maintain effective plasma concentrations, we prepared carbonates, esters and carbamates at the hydroxyl group of PEA. Chemical stability (pH 7.4) and stability in rat plasma and liver homogenate were evaluated by in vitro assays. Carbonates and carbamates resulted too labile and too resistant in plasma, respectively. Ester derivatives, prepared by conjugating PEA with various amino acids, allowed to modulate the kinetics of PEA release in plasma and stability in liver …

Malelcsh:MedicinePalmitic AcidsChemical synthesisAmidohydrolasesPalmitic acidchemistry.chemical_compoundHydrolysisPharmacokineticsIn vivoAnimalsProdrugsAmino AcidsEnzyme InhibitorsRats Wistarlcsh:Sciencechemistry.chemical_classificationPalmitoylethanolamideMultidisciplinarylcsh:Rfood and beveragesEstersProdrugAmidesAmino acidchemistryBiochemistryEthanolamineslcsh:QResearch ArticlePLOS ONE
researchProduct

Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison…

2010

The objectives of the study were (i) to investigate the effect of experimental parameters on the iontophoretic transport of granisetron, (ii) to identify the relative contributions of electromigration (EM) and electroosmosis (EO), (iii) to determine the feasibility of delivering therapeutic amounts of drug for the treatment of chemotherapy-induced nausea and vomiting and (iv) to test the in vitro results in a simple animal model in vivo. Preliminary in vitro studies using aqueous granisetron formulations investigating the effect of drug concentration (5, 10, 20 and 40 mM) and current density (0.1, 0.2, 0.3 mA cm(-2)) were performed using porcine ear skin. As expected, cumulative delivery in…

Malemedicine.drug_classSwinePharmaceutical ScienceIontophoresis/methodsPharmacologyIn Vitro TechniquesGranisetronAdministration CutaneousHigh-performance liquid chromatographyGranisetronPharmacokineticsIn vivoLimit of DetectionGranisetron/administration & dosage/pharmacokineticsSkin/metabolismMedicineAntiemeticAnimalsRats WistarChromatography High Pressure LiquidTransdermalSkinddc:615Iontophoresisbusiness.industryHalf-lifeIontophoresisAntiemetics/administration & dosage/pharmacokineticsRatsSerotonin Antagonists/administration & dosage/pharmacokineticsArea Under CurveAntiemeticsSerotonin Antagonistsbusinessmedicine.drugHalf-LifeEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

The ocular penetration of oral sparfloxacin in humans

1994

The penetration of sparfloxacin into the aqueous humor after oral administration was studied in 28 patients undergoing cataract surgery. Each patient received a single, oral dose of 400 mg of sparfloxacin. In eight other patients scheduled to undergo vitreal surgery, multiple daily oral doses were administered for a total amount of 1,000 mg. The aqueous levels were (mean +/- SEM) 0.127 +/- 0.036 microgram/ml to 0.404 +/- 0.159 microgram/ml from two to 24 hours after ingestion. In the vitreous, the mean drug level was 0.840 microgram/ml (range, 0.480 to 2.060 microgram/ml), from 4.3 to 8.0 hours after the most recent oral dose. Blood samples obtained at the same time as vitreous and aqueous …

Malemedicine.drug_classmedicine.medical_treatment[SDV]Life Sciences [q-bio]AntibioticsAdministration OralCataract ExtractionMicrobial Sensitivity TestsQuinolonesAqueous HumorPharmacokineticsAnti-Infective AgentsOral administrationVitrectomyMedicineIngestionHumansChromatography High Pressure LiquidAntibacterial agentAgedAged 80 and overChemotherapybusiness.industryCataract surgeryMiddle Agedeye diseases[SDV] Life Sciences [q-bio]Vitreous BodyOphthalmologySparfloxacinAnesthesiaFemalesense organsbusinessmedicine.drugFluoroquinolones
researchProduct